WILMINGTON, Mass. — CutisPharma announced the commercial availability of First-Metoprolol grape-flavored oral solution compounding kit. First-Metoprolol provides pharmacists with a convenient, high-quality, standardized way to compound an oral liquid metoprolol solution for patients who are not otherwise served by commercially available therapies, such as those who are unable to swallow solid oral dosing formulations.
“We are pleased to announce that, effective today, First-Metoprolol is commercially accessible to all pharmacies in the United States,” said Mike Radice, CutisPharma’s chief commercial officer. “The addition of First-Metoprolol to our overall portfolio of First Unit-of-Use Compounding Kits has been widely anticipated by our customers and will provide pharmacists with an expanded range of high-quality alternatives to traditionally compounded oral liquid suspensions and solutions.”
First-Metoprolol is now available in a 10 mg/mL strength in a convenient 300mL size. To allow additional flexibility for a variety of patient needs, an additional FIRST-Metoprolol 10 mg/mL 90mL size will be commercially available effective February 18, 2019.